Principal Investigator: Adam R. Konopka, Ph. D.

Aging is a risk factor for nearly all chronic diseases. The goal of this study is to investigate the effect that metformin, an anti-diabetic medication, has on the aging process in those who are insulin sensitive versus those who are insulin resistant. We are now recruiting people aged 40-75 years old who may be insulin resistant or at risk for type 2 diabetes to participate in the ANTHEM Aging Study.

You may qualify if you have one of the following:

• Are insulin resistant
• Have high blood sugar (100-125 mg/dL) or HbA1c (5.7-6.4%)
• Your doctor has told you that you are at risk of developing type 2 diabetes

If you do not know if you meet these criteria, we can evaluate for free. You may have increased risk of insulin resistance or high blood sugar if you have a BMI >30 kg/m2 or if you are not physically active.

Volunteers will undergo a health screening prior to enrollment. Those with known heart disease, diabetes, bleeding disorders, or other major illnesses do not qualify for the study.

Once admitted, visits may range from 10 minutes to five hours and will include blood and muscle samples, a body composition scan and an insulin sensitivity test. Participants will be compensated for their time, and metformin or placebo will be provided at no cost.

For more information contact our team at: aging.metformin.study@medicine.wisc.edu